RedHill Biopharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on RedHill Biopharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how RedHill Biopharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with RedHill Biopharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
The following section provides information on RedHill Biopharma Ltd’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into RedHill Biopharma Ltd's management and employees, unlock the full data with our company analytics monitoring tool.
Executives
Dr Richard Peters
Chairman Executive BoardDr Richard Peters has been the since September 2023. Prior to this, he served as the Global Head, Rare Diseases at Sanofi Genzyme. Previously, he served as the Chief Executive Officer at Merrimack Pharmaceuticals and Yumanity Therapeutics. He served as the Director at Aprea Therapeutics. He served as the Executive Chairman at TellBio. He also served as the corporate advisor at Aura Biosciences. He served in various medical leadership roles at Amgen, Onyx Pharmaceuticals, Genzyme, and Sanofi.
Fabrice Chouraqui
Chief Executive Officer; Chairman Executive BoardFabrice Chouraqui has been Chief Executive Officer and Executive Director of the company since March 2025. He also serves as the Director at OranoMed. Prior to this, he served as the Chief Executive Officer at Cellarity, Inc. Previously, he served as the President at Novartis Pharmaceuticals USA.
Dr Mark Pykett
Director; Vice Chairman Executive BoardDr Mark Pykett has been the Vice Chairman and Director of the company since December 2020. He also serves as the Chief Executive Officer and Director at Orogen Therapeutics and Director at Myopax. Prior to this, he served as the President and Chief Executive Officer at Myrtelle, Inc. He served as the Chief Scientific Officer at PTC Therapeutics. He served as the President and Chief Executive Officer at Agilis Biotherapeutics. He also served as the Chief Executive Officer at Navidea Biopharmaceuticals.
Kenneth Lynard
Chief Financial Officer Senior ManagementMr Kenneth Lynard has been the Chief Financial Officer of the company since October 2025. Prior to this, he served as Chief Financial Officer at Schoeller Allibert. Previously, he served as the Chief Financial Officer at Zentiva and Affidea. He also served as the Vice President Finance for Global Commercial Operations, R&D, and Manufacturing at Gilead Sciences.
Ruud van Outersterp
Secretary; Chief Legal Officer Senior ManagementMr Ruud van Outersterp has been the Chief Legal and Compliance Officer & Company Secretary of the company since 2025. Prior to this, he served as the Global Head of Legal and Company Secretary at ABN AMRO. Previously, he served as the Director at Dutch healthcare institution.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer